Overview
Lobbying Costs
None declared
Financial year: Jan 2014 - Dec 2014
Lobbyists (Full time equivalent)
5 Fte (6)
Lobbyists with EP accreditation
3
High-level Commission meetings
5
Lobbying Costs over the years
-
Info
Stichting Health Action International (HAI)
EU Transparency Register
44361352681-84 First registered on 30 Nov 2009
Goals / Remit
The mission of HAI is to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy. All regional offices share the same vision and common philosophies and work with their partners to achieve the targets that are set out in annual workplans; these targets are based on the three pillars of access to essential medicines; rational use of medicines; and democratisation of medicines policy. Though these targets have a common, global, aim, they are tailored to suit the prevailing local conditions for each region. Collaboration between the various groups within the 4 regions with the Global office leads to strong partnerships and a high level of commitment.
The work of HAI is based on three pillars: access to essential medicines; rational use of medicines; and democratisation of medicines policy. It encompasses patients and consumers in more than 70 countries worldwide; in Europe HAI represents the interests of approx. 120 concerned groups and individuals in 22 European countries (18 from the European Union).
A significant part of HAI Europe work lies in the field of advocacy and guiding medicine policy formulated at the European Parliament on behalf of consumers and patients in the European Union. This work is carried out in collaboration with various stakeholders, including public health orientated NGOs and Members of the European Parliament and is informed by high-level policy research and analysis. Campaigns carried out ensure that public awareness is raised to press decision-makers in governments and European institutions to introduce policies and enforce best practices in the field of improving public health.Main EU files targeted
EU proposal for a Trade Secrets Directive, EU Clinical Trial Regulation, Trans-atlantic Trade and Investment Partnership Agreement, EMA policies (Access to documents, adaptive licensing, scientific advice and COI policy), EMA discharge, the updated EU trade and investment strategy for jobs and growth, the Innovative Medicines Initiative, EU pharmacovigilance Regulation, EU Access to Documents Regulation, Horizon 2020, EU IP enforcement strategy vis-à-vis third countries, proposal for new rules on the EU Transparency Register.
Address
Head Office
Overtoom, 60/II
Amsterdam 1054HK
NETHERLANDS -
People
Total lobbyists declared
6
Employment time Lobbyists 100% 3 75% 2 50% 1 Lobbyists (Full time equivalent)
5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
3 accreditations were / are live (in bold) for the selected state of 22 Apr 2015
Name Start date End Date Ms Hannah VAN KOLFSCHOOTEN 14 Dec 2022 14 Dec 2023 Ms Janneke VAN OIRSCHOT 09 Dec 2022 09 Dec 2023 Mr Jaume VIDAL 04 Nov 2022 04 Nov 2023 Ms Ellie WHITE 27 Oct 2021 11 Feb 2022 Mr Jaume VIDAL 27 Oct 2021 27 Oct 2022 Mr Jaume VIDAL 19 Sep 2019 19 Sep 2020 Ms Ellie WHITE 14 Sep 2019 12 Sep 2020 Ms Ancel·la Santos Quintano 13 Oct 2018 25 Apr 2019 Mr Jaume VIDAL 13 Oct 2018 19 Sep 2019 Ms Ancel·la Santos Quintano 14 Oct 2017 13 Oct 2018 Mr Jaume VIDAL 20 Jul 2017 07 Jul 2018 Ms Tessel Mellema 07 Sep 2016 21 Jul 2017 Ms Ancel·la Santos Quintano 07 Sep 2016 07 Sep 2017 Ms Tessel Mellema 27 Aug 2015 26 Aug 2016 Ms Ancel·la Santos Quintano 27 Aug 2015 26 Aug 2016 Ms Aliénor Devalière 27 Aug 2015 23 Jun 2016 Ms Ancel·la Santos Quintano 01 May 2014 05 Jun 2015 Ms Aliénor Devalière 07 Jun 2014 05 Jun 2015 Mrs Aliénor Devalière 07 Jun 2014 27 Jan 2015 Ms Tessel Mellema 01 May 2014 05 Jun 2015 Mrs Ancel·la Santos Quintano 01 May 2014 27 Jan 2015 Ms Tessel Mellema 25 Jun 2013 01 May 2014 Mrs Ancel·la Santos Quintano 30 May 2013 01 May 2014 Ms Katrina Perehudoff 22 Sep 2012 17 Jun 2013 Ms Tessel Mellema 20 Sep 2012 25 Jun 2013 Complementary Information
On behalf of HAI Europe, the persons listed below have had, during the reporting period (2013), four or more contacts with members or officials of the EU institutions, or they have spent 20 percent or more of their working time on behalf of HAI Europe carrying out such activities.
1. Tessel Mellema
2. Ancel·la Santos Quintano
3. Tim Reed
4. Aliénor DevalièrePerson in charge of EU relations
Ms Ancel·la Santos Quintano (Policy Advisor)
Person with legal responsibility
Mr Tim Reed (Executive Director HAI)
-
Categories
Category
III - Non-governmental organisations
Subcategory
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
HAI Europe is one of the 4 HAI regional coordination offices; it works in close collaboration with the HAI regional office for Asia & the Pacific (based in Penang, Malaysia), for Africa (based in Nairobi, Kenya) and for Latin America (based in Lima, Peru). The entire HAI network is coordinated from the HAI Global office located in Amsterdam, the Netherlands.
HAI Europe is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins, Prescrire, the Trans-Atlantic Consumer Dialogue, the Medicines in Europe Forum and the Patients and Consumers Working Party (PCWP)and Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency. HAI Europe is a signatory to the Alliance for Lobby Transparency and Ethics Regulation in the EU (ALTER-EU). All these organisations have deep-seated knowledge of European public health policy, besides having access to international experts on a variety of health issues (notably pharmacovigilance). In addition HAI Europe enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required.
HAI Europe collaborates with WHO on certain projects and is eligible to work with the European Medicines Agency.Member organisations
Arab Resource Collective(20),
Baby Milk Organisation(1500),
BUKO Pharma-Kampagne(203),
Club for Protection of Consumers Interests in Latvia(60),
Drug Utilization Research Group Armenia(6),
Déclaration de Berne(21000),
DIFAM, Germany(123),
EKPIZO, Greece(230),
IBFAN-Gifa(800),
IDDT, U.K,(1300),
KEPKA, Greece(2220),
La Revue Prescrire(650),
Medico International(58),
Physicials for Social Responsibility(800),
Swissmedic(280),
Medicus Mundi Switzerland(60),
Wemos, The Netherlands(110),
Salud por Derecho, Spain(20),
Verbraucherzentrale Bundesverband(300) -
Financial Data
Closed financial year
Jan 2014 - Dec 2014
Lobbying costs for closed financial year
None declared
EU grant income for closed financial year
218,000 € (Source: CHAFEA)
Other financial info
The above estimated costs in representing HAI interests to European Institutions in 2013 was €145.000
Grants received in 2013:
Executive Agency for Health & Consumers : 218.000 euro
Open Society Foundation : €70.965
Own contribution: €93.188
Contributions from members: €6.210
Reference:http://haieurope.org/wp-content/uploads/2014/04/HAI-Financial-Statements-2013.pdf
As part of the HAI network, HAI Europe is subject to rigorous and robust monitoring & evaluation protocols, evolved in partnership with the Dutch government. In addition, a dedicated M&E protocol for each of the strategic objectives in the annual work programme has been constructed to provide a transparent and valid assessment of each project; this is reflected in the Annual and Financial reports listed on the HAI website each year.
HAI Europe maintains a strict policy to avoid conflicts of interest: no funds can be taken from the pharmaceutical industry. In addition, any financial relationship, or other beneficial interests, that could impact on working with HAI must be declared on a ‘Competing Interests form’ which is applicable to all members each year.
-
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
None
Other activities
HAI Europe activities in 2013 were related to the following EU initiatives:
Clinical Trials Regulation
Transparency Directive
EU Access to Documents Regulation
EU Customs Regulation
EU Thailand Free Trade Agreement
EU US Free Trade Agreement
EU-Mercosur Free Trade Agreement
EU-India Free Trade Agreement
Anti-Counterfeiting Trade Agreement
European Research & Innovation Framework, Horizon 2020
Staff regulations
EMA policies on: the handling of potential conflicts of interest; ethical and GCP aspects of clinical trails in third countries; identification of commercially confidential information- Meetings
Meetings
5 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 07 Oct 2021 Location video conference Subject COVID Vaccines Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Caroline Boeshertz (Cabinet member)
Other Lobbyists -
Date 03 Jun 2021 Location video-conference Subject Trade in relation to COVID-related technologies Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Caroline Boeshertz (Cabinet member)
- Cristina Rueda Catry (Cabinet member)
Other Lobbyists -
Date 15 May 2018 Location Brussels Subject Access to medicines in poor countries Cabinet Cabinet of Vice-President Cecilia Malmström Portfolio Trade Attending - Pedro Velasco Martins (Cabinet member)
- Maria Asenius (Cabinet member)
Other Lobbyists -
Date 15 May 2018 Location Brussels Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Annika Nowak (Cabinet member)
Other Lobbyists - European Federation of Allergy and Airways Diseases Patients' Associations
- International Diabetes Federation European Region
- EUROPEAN ORGANISATION FOR RARE DISEASES
- European Patients' Forum (EPF)
- ASDM Consulting
- European Public Health Alliance
- Bureau Européen des Unions de Consommateurs
- European Cancer Patient Coalition
-
Date 18 Oct 2016 Location Brussels Subject Access to medicines Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Meetings